A new post-hoc analysis confirmed in humans that CEREBIOME® can increase significantly brain-derived neurotrophic factor (BDNF) serum levels as observed several years ago in preclinical models. These new results bring more understanding about the potential modes of action of CEREBIOME® on the gut-brain axis, especially on depressive population.
Previously, in 2018, Kazemi et al. followed 110 adults suffering from mild to moderate depression. They found out that CEREBIOME®, used as an adjunct therapy to conventional antidepressant treatment, had contributed to a significant reduction of Beck’s Depression Inventory (BDI) depression score from 18 down to 9 on average, and increased serotonin precursors after eight weeks of intake. These results are clinically significant, showing the patients were now categorized with “minimal depression” according to the validated assessment scale. More precisely, the CEREBIOME® group showed a decrease in the blood kynurenine/tryptophan ratio, which suggests that tryptophan was diverted toward the synthesis of serotonin (p<0.05) and away from the inflammatory pathway (p<0.05) compared to the placebo group.
Serum BDNF levels are lower in depressed patients and they increase after a long course of antidepressant treatment. In this new post-hoc analysis, the investigators looked at the participants’ BDNF serum levels. Results show that the probiotic formula CEREBIOME® significantly increased BDNF levels compared to the placebo group (p=0.02) and to the prebiotic group (p<0.001), which inversely correlated with depression severity compared to placebo (p=0.012).
“This is a great example where the clinical trial observations matched the observations from the preclinical studies,” explains Lucie Lingrand, specialist of the brain-gut axis at Lallemand Health Solutions. The increase of BDNF identified in animal model by Ait Belgnaoui in 2014, appeared to translate to humans. It may be one of the mechanisms of action by which CEREBIOME® reduces depression in humans, in addition to all the demonstrated modes of action to date”, details Lucie Lingrand.
To read the full post-hoc analysis, visit: http://www.jnmjournal.org/journal/view.html?doi=10.5056/jnm20079
To find out more about CEREBIOME®, an innovative ingredient, visit cerebiomebylallemand.com and download the White paper to explore the power of psychobiotics.
Reference: Heidarzadeh-Rad, N.,et al (2020). Effects of a Psychobiotic Supplement on Serum Brain-derived Neurotrophic Factor Levels in Depressive Patients: A Post Hoc Analysis of a Randomized Clinical Trial. Journal of Neurogastroenterology and Motility, 26(4), 486-495.
For other use than DFS, based on emerging science
About CEREBIOME®
CEREBIOME® (previously known as Probio’Stick®), is Lallemand Health Solutions proprietary combination of Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175. CEREBIOME® is a unique and strongly documented psychobiotic formulation developed by the Rosell® Institute for Microbiome and Probiotics by Lallemand. It is the most documented psychobiotic supported by five clinical studies, over ten mechanistic studies and several pre-clinical studies allowing to highlight eight mechanisms of action on the brain-gut axis. CEREBIOME® helps alleviate the physical and psychological symptoms of stress and feelings of anxiety.
About Lallemand Health Solutions. Quality probiotics. Complete solutions.
Founded in 1934, Lallemand Health Solutions is a vertically integrated probiotic manufacturer specializing in the research, development and manufacturing of ready-to-market and custom probiotic formulations. Its products target specific populations and health segments including babies’ health, gut health, natural defenses, women’s health, brain-gut axis, skin health, metabolism, oral health and sport. Probiotics are produced in cutting-edge plants certified to the highest quality standards. More than 600 probiotic formulas are currently marketed in over 60 countries across five continents. From lab to shelf, Lallemand Health Solutions has the full control and expertise to produce premium probiotic solutions, blends and custom formulations as each development step is expertly supported by internal quality insurance, regulatory affairs, research and development, scientific affairs, technical support, sales and marketing teams.
About the Rosell® Institute for Microbiome and Probiotics by Lallemand
The Rosell® Institute for Microbiome and Probiotics by Lallemand, Lallemand Health Solutions’ research and development center located at the National Research Council of Canada in Montreal, develops partnerships with key scientific experts in order to study the human microbiome and how probiotic supplements can be used as a mean to improve or maintain health in specific populations or health segments. The research team has published over 330 publications including 160 clinical studies.
̶ 30 ̶
CONTACT
Marilou Luneau, Content manager, Lallemand Health Solutions
mluneau@lallemand.com
514-629-4124